OXURION to Participate in Upcoming Investor Meetings
05 Agosto 2021 - 5:45PM
OXURION to Participate in Upcoming Investor Meetings
Leuven, BELGIUM, Boston, MA, US - August 5th, 2021
– 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, with a clinical stage portfolio in
vascular retinal disorders, today announces its management will
participate and meet with investors at the following
upcoming virtual meetings:
- 2021 Wedbush PacGrow Healthcare
Virtual Conference
August 10-11, 2021Panel presentation (Goldeneye)
scheduled on August 11 at 9:45 AM ET
- H.C. Wainwright Ophthalmology Conference
August 17, 2021Pre-Recorded CEO Presentation
available starting on August 17 at 7:00 AM ETPanel presentation
(Vision Repair Beyond Traditional Anti-VEGF) scheduled on August 17
at 12:00 PM ET
For more information, please visit Oxurion’s
events
page:www.oxurion.com/news-events#view-conferences_events-page
END
For further information please
contact:
Oxurion NVWouter Piepers, Global Head of Investor Relations&
Corporate CommunicationsTel: +32 16 75 13 10 / +32 478 33 56
32wouter.piepers@oxurion.com |
EU MEDiSTRAVA ConsultingDavid Dible/ Sylvie Berrebi/Frazer HallTel:
+44 20 7638 9571oxurion@medistrava.com USWestwicke, an ICR
CompanyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to better preserve
vision in patients with retinal vascular disorders including
diabetic macular edema (DME), the leading cause of vision loss in
diabetic patients worldwide as well as other conditions, including
wet age-related macular degeneration (AMD) and retinal vein
occlusion (RVO).
Oxurion is aiming to build the leading global
franchise in the treatment of retinal vascular disorders based on
the successful development of its two novel therapeutics:
- THR-687 is a pan-RGD integrin antagonist that is initially
being developed as a potential first line therapy for DME patients.
Positive topline results in a Phase 1 clinical study assessing
THR-687 as a treatment for DME were announced in 2020. Oxurion is
currently conducting a Phase 2 clinical trial evaluating THR-687 in
patients with DME. THR-687 also has the potential to deliver
improved treatment outcomes for patients with wet AMD and RVO.
- THR-149 is a plasma kallikrein inhibitor being developed as a
potential new standard of care for the 40% of DME patients who
respond sub optimally to anti-VEGF therapy. THR-149 has shown
positive topline Phase 1 results for the treatment of DME. The
company is currently conducting a Phase 2 clinical trial evaluating
multiple injections of THR-149 in DME patients who previously
responded sub optimally to anti-VEGF therapy.
Oxurion is headquartered in Leuven, Belgium, and
is listed on the Euronext Brussels exchange under the symbol OXUR.
More information is available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Apr 2023 a Apr 2024